Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$2.84 - $3.92 $89,403 - $123,401
31,480 Added 26.29%
151,235 $588,000
Q4 2022

Feb 14, 2023

BUY
$2.48 - $5.93 $148,033 - $353,967
59,691 Added 99.38%
119,755 $407,000
Q3 2022

Nov 14, 2022

BUY
$4.08 - $5.82 $22,648 - $32,306
5,551 Added 10.18%
60,064 $328,000
Q2 2022

Aug 15, 2022

BUY
$4.15 - $8.37 $226,228 - $456,273
54,513 New
54,513 $246,000
Q1 2022

May 16, 2022

SELL
$5.91 - $14.38 $1.23 Million - $3 Million
-208,526 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$5.21 - $8.61 $81,249 - $134,272
15,595 Added 8.08%
208,526 $1.34 Million
Q3 2021

Nov 15, 2021

BUY
$4.45 - $10.63 $499,107 - $1.19 Million
112,159 Added 138.86%
192,931 $1.12 Million
Q2 2021

Aug 16, 2021

SELL
$8.11 - $11.11 $21,086 - $28,886
-2,600 Reduced 3.12%
80,772 $834,000
Q1 2021

May 17, 2021

BUY
$9.85 - $17.69 $821,214 - $1.47 Million
83,372 New
83,372 $877,000
Q4 2020

Feb 16, 2021

SELL
$14.15 - $17.19 $458,714 - $557,265
-32,418 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$14.14 - $19.71 $458,390 - $638,958
32,418 New
32,418 $473,000
Q1 2020

May 15, 2020

SELL
$14.38 - $27.72 $774,492 - $1.49 Million
-53,859 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$9.23 - $19.67 $497,118 - $1.06 Million
53,859 New
53,859 $1.03 Million
Q2 2018

Aug 14, 2018

SELL
$12.0 - $19.88 $145,884 - $241,681
-12,157 Closed
0 $0
Q1 2018

May 15, 2018

SELL
$9.92 - $17.25 $105,935 - $184,212
-10,679 Reduced 46.76%
12,157 $163,000
Q4 2017

Feb 14, 2018

BUY
$9.15 - $11.99 $43,563 - $57,084
4,761 Added 26.34%
22,836 $219,000
Q3 2017

Nov 14, 2017

BUY
$8.15 - $11.16 $147,311 - $201,717
18,075
18,075 $198,000

Others Institutions Holding KPTI

About Karyopharm Therapeutics Inc.


  • Ticker KPTI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 79,806,600
  • Market Cap $611M
  • Description
  • Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...
More about KPTI
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.